📊 SRTS Key Takeaways
Is Sensus Healthcare, Inc. (SRTS) a Good Investment?
Sensus Healthcare faces severe operational challenges with accelerating net losses (-216% YoY) despite flat revenue and a healthy gross margin of 43%, indicating structural inefficiencies in cost management and market execution. While the fortress balance sheet ($22.1M cash, 9.72x current ratio, zero debt) provides survival runway, the company must demonstrate revenue acceleration and operating leverage to justify investment; current trajectory suggests persistent cash burn without near-term profitability visibility.
Why Buy Sensus Healthcare, Inc. Stock? SRTS Key Strengths
- Fortress balance sheet with $48.1M equity and zero long-term debt
- Exceptional liquidity with 9.72x current ratio and $22.1M cash reserves
- Respectable 43.2% gross margin indicates product market fit and pricing power
- Positive free cash flow generation ($332K) despite net losses
SRTS Stock Risks: Sensus Healthcare, Inc. Investment Risks
- Flat revenue growth (0% YoY) with no organic expansion trajectory
- Accelerating net losses deteriorating 216% YoY with widening operating margin (-37.5%)
- Massive operating expense base consuming 80% of gross profit, indicating structural inefficiency
- Weak FCF margin (1.2%) and minimal insider activity suggest limited management confidence
- Cash depletion risk if losses continue without revenue inflection or aggressive cost reduction
Key Metrics to Watch
- Quarterly revenue growth acceleration above 5% YoY
- Operating margin inflection toward breakeven through cost rationalization
- Free cash flow margin expansion above 5% demonstrating operational efficiency
Sensus Healthcare, Inc. (SRTS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 1.2% FCF margin may limit capital allocation flexibility. Strong liquidity with a 9.72x current ratio provides a solid financial cushion.
SRTS Profit Margin, ROE & Profitability Analysis
SRTS vs Healthcare Sector: How Sensus Healthcare, Inc. Compares
How Sensus Healthcare, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sensus Healthcare, Inc. Stock Overvalued? SRTS Valuation Analysis 2026
Based on fundamental analysis, Sensus Healthcare, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sensus Healthcare, Inc. Balance Sheet: SRTS Debt, Cash & Liquidity
SRTS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sensus Healthcare, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.41 reflects profitable operations.
SRTS Revenue Growth, EPS Growth & YoY Performance
SRTS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $6.9M | -$943.0K | $-0.06 |
| Q2 2025 | $7.3M | -$1.0M | $-0.06 |
| Q1 2025 | $8.3M | $2.3M | $0.14 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sensus Healthcare, Inc. Dividends, Buybacks & Capital Allocation
SRTS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sensus Healthcare, Inc. (CIK: 0001494891)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SRTS
What is the AI rating for SRTS?
Sensus Healthcare, Inc. (SRTS) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SRTS's key strengths?
Claude: Fortress balance sheet with $48.1M equity and zero long-term debt. Exceptional liquidity with 9.72x current ratio and $22.1M cash reserves.
What are the risks of investing in SRTS?
Claude: Flat revenue growth (0% YoY) with no organic expansion trajectory. Accelerating net losses deteriorating 216% YoY with widening operating margin (-37.5%).
What is SRTS's revenue and growth?
Sensus Healthcare, Inc. reported revenue of $27.5M.
Does SRTS pay dividends?
Sensus Healthcare, Inc. does not currently pay dividends.
Where can I find SRTS SEC filings?
Official SEC filings for Sensus Healthcare, Inc. (CIK: 0001494891) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SRTS's EPS?
Sensus Healthcare, Inc. has a diluted EPS of $-0.47.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SRTS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Sensus Healthcare, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SRTS stock overvalued or undervalued?
Valuation metrics for SRTS: ROE of -16.0% (sector avg: 15%), net margin of -28.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SRTS stock in 2026?
Our dual AI analysis gives Sensus Healthcare, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SRTS's free cash flow?
Sensus Healthcare, Inc.'s operating cash flow is $528.0K, with capital expenditures of $196.0K. FCF margin is 1.2%.
How does SRTS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -28.1% (avg: 12%), ROE -16.0% (avg: 15%), current ratio 9.72 (avg: 2).